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A B S T R A C T
Purpose
The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial established
perioperative epirubicin, cisplatin, and ﬂuorouracil chemotherapy as a standard of care for patients
with resectable esophagogastric cancer. However, identiﬁcation of patients at risk for relapse
remains challenging. We evaluated whether pathologic response and lymph node status after
neoadjuvant chemotherapy are prognostic in patients treated in the MAGIC trial.
Materials and Methods
Pathologic regression was assessed in resection specimens by two independent pathologists using
the Mandard tumor regression grading system (TRG). Differences in overall survival (OS) according
to TRG were assessed using the Kaplan-Meier method and compared using the log-rank test.
Univariate and multivariate analyses using the Cox proportional hazards method established the
relationships among TRG, clinical-pathologic variables, and OS.
Results
Three hundred thirty resection specimens were analyzed. In chemotherapy-treated patients with
a TRG of 1 or 2, median OSwas not reached, whereas for patients with a TRG of 3, 4, or 5, median OS
was 20.47 months. On univariate analysis, high TRG and lymph node metastases were negatively
related to survival (Mandard TRG 3, 4, or 5: hazard ratio [HR], 1.94; 95% CI, 1.11 to 3.39; P = .0209;
lymph nodemetastases: HR, 3.63; 95%CI, 1.88 to 7.0; P, .001). Onmultivariate analysis, only lymph
node status was independently predictive of OS (HR, 3.36; 95% CI, 1.70 to 6.63; P , .001).
Conclusion
Lymph node metastases and not pathologic response to chemotherapy was the only independent
predictor of survival after chemotherapy plus resection in the MAGIC trial. Prospective evaluation of
whether omitting postoperative chemotherapy and/or switching to a noncross-resistant regimen in
patients with lymph node-positive disease whose tumor did not respond to preoperative epirubicin,
cisplatin, and ﬂuorouracil may be appropriate.
J Clin Oncol 34:2721-2727. © 2016 by American Society of Clinical Oncology. Licensed under the
Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/
INTRODUCTION
Patients with resectable gastric or gastroesopha-
geal adenocarcinoma frequently undergo neo-
adjuvant therapy before surgical resection. The
aim of this treatment is to down-stage primary
tumors to achieve a microscopically complete
resection, and to eliminate radiologically occult
micrometastases, which may result in recurrent
metastatic disease.1-4 Despite multimodal treat-
ment, up to half of the patients who undergo
surgery will subsequently relapse and die of their
cancer. Identiﬁcation of patients requiring addi-
tional therapy to prevent relapse remains chal-
lenging. No prognostic marker is currently
available beyond standard pathologic Union for
International Cancer Control TNM staging for
patients with gastroesophageal cancer who receive
neoadjuvant treatment.5-8
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The UK Medical Research Council Adjuvant Gastric Infu-
sional Chemotherapy (MAGIC) trial was an open-label, multi-
center, phase III randomized trial comparing the effect of six cycles
of perioperative epirubicin, cisplatin, and infused ﬂuorouracil
(ECF) chemotherapy plus surgery with surgery alone in patients
with resectable gastroesophageal cancer.2 Patients treated with
perioperative chemotherapy demonstrated improved overall sur-
vival (OS) compared with patients treated with surgery alone,
and perioperative ECF chemotherapy is now recommended for selected
patients by both the National Comprehensive Cancer Network and
European Society for Medical Oncology guidelines.9,10 However, two
key questions remain unanswered: whether we can deﬁne any bio-
marker that allows identiﬁcation of patients at higher risk for recurrence
after perioperative therapy and surgery and whether these high-risk
patients might beneﬁt from treatment with a different regimen. The
latter question can only be answered by a randomized controlled trial;
however, in an attempt to address theﬁrst question, hereinwe report the
relationships among pathologic response, lymph node metastases,
selected molecular abnormalities, neoadjuvant ECF chemotherapy,
and survival in the MAGIC trial.
MATERIALS AND METHODS
Analysis of Pathologic Tumor Regression
Representative blocks with primary tumor or complete pathologic
response were chosen by local pathologists and were collected centrally.
Hematoxylin and eosin-stained slides were reviewed by two pathologists
who were blinded to the treatment arm and graded for pathologic re-
sponse according to the Mandard tumor regression grading (TRG)
system.11 This system classiﬁes pathologic response as follows: TRG 1
(complete regression/ﬁbrosis with no evidence of tumor cells), TRG 2 (ﬁbrosis
with scattered tumor cells), TRG 3 (ﬁbrosis and tumor cells with a dominance
of ﬁbrosis), TRG 4 (ﬁbrosis and tumor cells with a dominance of tumor cells),
and TRG 5 (tumor without evidence of regression). In cases of disagreement
between pathologists, a consensus was sought by joint rereview and discussion.
Histopathologic variables that had previously been collected were retrieved
from the MAGIC database retained by the Medical Research Council
Clinical Trials Unit at UCL, London, United Kingdom. The histologic
tumor type according to Lauren’s classiﬁcation12 was determined
preferentially on the basis of pretreatment tumor biopsies and resection
specimens if a biopsy was not available. The study was approved by the
UK national ethical approval system before study commencement.
Analysis of Tissue Biomarkers
Mutations in KRAS, BRAF, PIK3CA, TP53, and expression of phos-
phatase and tensin homolog (PTEN) and human epidermal growth factor
receptor 2 (HER2) were assessed as previously described.13-15 The deﬁnition
for HER2 positivity used was immunohistochemically 3+ or immunohis-
tochemically 2+ and bright-ﬁeld dual-probe in situ hybridization positive.
Statistical Methods
OSwas calculated from surgery to death from any cause or last date of
follow-up.2 Date of surgery was selected as the baseline for biomarker
analysis to avoid bias because patients treated with chemotherapy after
being randomly assigned have a longer postrandomization survival. Date
of surgery could not be conﬁrmed for nine patients in the chemotherapy-
plus-surgery arm, and these patients were excluded from the survival
analyses. Differences in OS stratiﬁed by Mandard TRG were assessed using
the Kaplan-Meier method and compared using the log-rank test. A P value
of , .05 was considered signiﬁcant.
x2 tests were used to assess the effect of tissue biomarker status
(KRAS, BRAF, PIK3CA, TP53, PTEN, and HER2) on pathologic response
rate. The effect of tissue biomarker status on OS has previously been
described.13-15
Univariate and multivariate analyses using the Cox proportional
hazards method were performed to establish the relationships among age,
sex, World Health Organization performance status (0 v 1), localization of
the primary tumor, Lauren’s classiﬁcation, TRG status, and presence of
lymph node metastases on OS. Variables with a P value of , .05 in
univariate analysis were included in the multivariate analysis.
RESULTS
Tumor Regression Grade, Lymph Node Status, and
Patient Survival
Five hundred three patients were randomly assigned in the
MAGIC trial, 473 (94%) of whom underwent surgery. Three
hundred thirty patients (171 from the surgery-alone arm, 159 from
the chemotherapy-plus-surgery arm) had tissue available for tu-
mor regression grading, representing 70% of patients who un-
derwent surgery within the trial (Fig 1). Baseline characteristics of
patients assessed for Mandard TRG are listed in Table 1. Consistent
with the entire MAGIC trial population, most patients were male
and most tumors were gastric cancers (76%) and intestinal type
(80%). There was no signiﬁcant difference in OS between patients
treated with chemotherapy with and without tissue available for
analysis (median OS, 23.1 months v 21.6 months, respectively;
P = .264; Appendix Table A1, online only). The TRG results for
patients treated with neoadjuvant chemotherapy were as follows:
TRG 1 (n = 8, 5%); TRG 2 (n = 29, 18%); TRG 3 (n = 53, 34%);
TRG4 (n= 46, 29%); andTRG5 (n= 23, 14%). Tumor regression-like
changes were also seen in patients treated with surgery alone in the
following proportions: TRG 1 (none); TRG 2 (n = 3, 2%); TRG 3
(n = 14, 8%); TRG 4 (n = 41, 24%); and TRG 5 (n = 113, 66%;
Fig 2). The interobserver agreement between the two pathologists
Patients who underwent
resection
(n = 229)
Patients with tumor
available for tumor
regression analysis
(n = 159)
All patients randomly assigned in the MAGIC trial
(N = 503)
Patients treated with
chemotherapy plus surgery
(n = 250)
Patients treated with
surgery alone
(n = 253)
Patients who underwent
resection
(n = 244)
Patients with tumor 
available for tumor 
regression analysis
(n = 171)
Fig 1. CONSORT diagram summarizing the analysis of pathologic tumor re-
gression grading in the Medical Research Council Adjuvant Gastric Infusional
Chemotherapy (MAGIC) trial. Tumor regressionwas assessed by two independent
pathologists using the Mandard tumor regression grading system.
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for TRG 1 to 5 was substantial, with a kappa of 0.64, which in-
creased to 0.70 as expected when TRG was grouped as TRG 1 and 2
(responders) versus TRG 3 to 5 (nonresponders). Tumors from
patients treated with neoadjuvant chemotherapy were signiﬁcantly
more likely to show signiﬁcant tumor regression (TRG 1 or 2;
P , .001 by Fisher’s exact test). Pathologic response to chemo-
therapy was not signiﬁcantly associated with any clinicopathologic
variable, including age, sex, site of tumor, or histologic subtype
(Appendix Table A2, online only).
Because the survival of patients with TRG 1 and 2 was similar
(data not shown) and the survival of patients with TRG 3, 4, or 5
also tracked together, the data set was dichotomized into two
groups: TRG 1 or 2 (TRG 1-2) versus TRG 3, 4, or 5 (TRG 3-5) for
further analyses (Table 2). Median OS for chemotherapy-treated
patients with TRG 1-2 was not reached (lower limit of 95% CI,
17.28 months), whereas patients with a TRG of 3-5 had a median
OS of 20.47 months (hazard ratio [HR], 1.94; 95% CI, 1.11 to 3.39;
P = .0209; Fig 3). Five-year OS for chemotherapy-treated pa-
tients with TRG 1-2 was 58.8% (95% CI, 40.3% to 73.3%),
whereas for chemotherapy-treated patients with TRG 3-5, it was
28.9% (95% CI, 19.5% to 38.9%), HR, 1.94 (95% CI, 1.11 to
3.39; P = .021).
Details on lymph node dissection were available for 272
patients: in 138 patients (51%), fewer than 15 nodes were dis-
sected; in 60 patients (22%), 15 to 20 lymph nodes were dissected;
in 28 patients (10%), 21 to 25 lymph nodes were dissected; and in
46 patients (17%), more than 25 lymph nodes were dissected. The
median number of lymph nodes removed was similar in the
chemotherapy-plus-surgery arm (13; range, 0 to 63) and the
surgery-alone arm (16; range, 0 to 91); this difference was not
statistically signiﬁcant (two-sample Mann-Whitney test P = .17).
Univariate Cox regression analysis including age, sex, per-
formance status, site of primary tumor, lymph node status, and
TRG demonstrated that both TRG (1-2 v 3-5) and lymph node
status (node-negative [ypN0] v node-positive [ypN+]) were sig-
niﬁcantly associated with OS in chemotherapy-treated patients
(TRG 3-5: HR, 1.94; 95% CI, 1.11 to 3.39; P = .0209; ypN+: HR,
3.63; 95% CI, 1.88 to 7.0; P = .0001; Appendix Table A3, online
only). Multivariate analysis including TRG and lymph node status
performed in 110 patients for whom all clinical-pathologic in-
formation were available demonstrated that the presence of lymph
nodemetastases was the only factor independently predictive of OS
in patients after neoadjuvant chemotherapy (HR, 3.36; 95% CI,
1.70 to 6.63; P , .001; Appendix Table A4, online only).
Table 1. Patient Characteristics
Characteristic
Surgery Chemotherapy Plus Surgery
No. (%) No. (%)
Age category, years
, 60 73 (42.7) 71 (44.7)
60 to , 70 59 (34.5) 52 (32.7)
$ 70 39 (22.8) 36 (22.6)
Sex
Female 46 (26.9) 31 (19.5)
Male 125 (73.1) 128 (80.5)
WHO score
Normal activity 117 (68.4) 111 (69.8)
Restricted 54 (31.6) 48 (30.2)
Site
Lower esophagus 22 (12.9) 22 (13.8)
Esophagogastric junction 19 (11.1) 16 (10.1)
Stomach 130 (76.0) 121 (76.1)
Histology
Diffuse 34 (20.0) 24 (15.1)
Intestinal 124 (72.5) 130 (81.7)
Mixed, other 10 (5.8) 2 (1.3)
Not assessable 3 (1.7) 3 (1.9)
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Fig 2. Tumor regression grade (TRG) and treatment in the Medical Research
Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial. Proportion of
patients in each treatment arm according to TRG category. Tumors from patients
treated with neoadjuvant chemotherapy were signiﬁcantly more likely to show
substantial tumor regression (TRG 1 or 2) than were tumors from patients treated
with surgery alone (P , .001).
Table 2. Overall Survival From Surgery Stratiﬁed by Mandard TRG in Patients
Treated With Chemotherapy Plus Surgery
Mandard
TRG
Median
Survival HR (95% CI) P*
Mandard TRG (1 and 2 v 3 v 4 v 5)
1-2 Not reached† .098
3 22.51 1.86 (1.01 to 3.43)
4 20.47 1.84 (0.97 to 3.49)
5 19.15 2.43 (1.17 to 5.04)
Mandard TRG (1 and 2 v 3 and 4 and 5)
1-2 Not reached† 1.94 (1.11 to 3.39) .0209
3-5 20.47
Abbreviations: HR, hazard ratio; TRG, tumor regression grade.
*Cox regression method.
†Greater than last censoring time.
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A statistical model was created containing four groups of
chemotherapy-treated patients; (A) ypN0 and TRG 1 or 2 (node-
negative responders); (B) ypN1+ and TRG 1 or 2 (node-positive
responders); (C) ypN0 and TRG 3, 4, or 5 (node-negative non-
responders); and (D) ypN1+ and TRG 3, 4, or 5 (node-positive
nonresponders). The median OS for all node-negative patients
(groups A and C, regardless of TRG status) was not reached be-
cause it was greater than the longest censoring time, whereas
the median OS for node-positive responders (group B) was
17.3 months (95% CI, 0.5 to not reached) and that for node-
positive nonresponders (group D) was 15.5 months (95% CI,
10.2 to 19.2 months); these differences were statistically signif-
icant (P , .001; Fig 4). The 5-year OS rates for groups A, B, C,
and D were 66.0% (95% CI, 36.5% to 84.3%), 50.0% (95% CI,
20.9% to 73.6%), 71.8% (95% CI, 44.3% to 87.4%), and 16.2%
(95% CI, 7.2% to 28.4%), respectively (P = .001). In comparison,
median OS in the surgery-alone arm for node-positive patients
(with TRG results available) was 19.0 months (95% CI, 14.1 to
25.0 months).
Correlation of TRG and Lymph Node Status With
Molecular Biomarker Status
Mutations in KRAS (codons 12 and 13), BRAF, PIK3CA
(exons 9 and 20), and TP53 (exons 4-8) were present in 6.4%,
0.7%, 5%, and 37.9% of patients treated with chemotherapy who
had TRG status available, respectively. TRG 1-2 response was not
documented in any patient with a KRAS, BRAF, or PIK3CA
mutation; however, none of these genes was individually statisti-
cally signiﬁcantly associated with pathologic response to chemo-
therapy. When all KRAS, BRAF, and PIK3CA mutations (n = 16)
were combined as an oncogene mutant group, the association
with lack of response reached borderline statistical signiﬁcance
(P = .055). Fourteen of 36 patients (38%) with a TP53mutation had
a TRG 1 or 2 pathologic response compared with 14 of 59 patients
(24%) who did not; this difference was not statistically signiﬁcant
(P = .116). In patients with low or no PTEN expression (38% of the
cohort) with TRG results, 12 of 56 (21%) had TRG 1-2, compared
with 15 of 92 patients (16%) with intact PTEN. One of 13 patients
(7.7%) who were HER2 positive with a TRG result had a TRG of
1-2, compared with 31 of 141 (21.9%) who were HER2 negative
(P = .224). There was no statistically signiﬁcant association
between KRAS, BRAF, PIK3CA, TP53, PTEN, or HER2 status
and the presence of involved lymph nodes in the resection
specimen.
DISCUSSION
To our knowledge, this study is the ﬁrst to report the results of
interaction between the prognostic effects of centrally analyzed
tumor regression and other clinicopathologic variables on survival
in a randomized trial with a nonchemotherapy control arm for
perioperatively treated gastroesophageal cancer. We demonstrated
on univariate analysis that tumor regression (TRG 1 or 2, eg,
complete pathologic response or low number of residual tumor
cells) is associated with improved OS in chemotherapy-treated
patients, but not in surgery-alone–treated patients. However, the
relationship between TRG and survival is not independent of
lymph node status, which was the only independent predictor of
survival in patients treated with chemotherapy in this study.
A strength of our study is that all available hematoxylin and
eosin slides from the resection specimens were subjected to central
pathology review, which guaranteed relatively uniform classiﬁca-
tion of tumor regression according to Mandard.11,12 Previously
published studies in this ﬁeld were all retrospective, were usually
performed with single-center nonrandomized cohorts, used a va-
riety of different tumor regression grading systems, and lacked
a surgery-alone control group. Our results validate the results of
the largest previous uncontrolled series, which also reported that
lymph node status is more important as a prognostic variable than
tumor regression.16 This ﬁnding underscores the paramount
importance of adequate lymph node resection for accurate staging
and, hence, prognosis prediction in patients with gastroesoph-
ageal cancer.16-18 Because there is no independent effect of
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Fig 3. Overall survival by tumor regression
grade (TRG) in patients treated with chemo-
therapy plus surgery in the Medical Research
Council Adjuvant Gastric Infusional Chemo-
therapy (MAGIC) trial. Patients were dichotomized
into two groups: TRG 1-2 responders and TRG
3-4-5 nonresponders. Differences in overall
survival were assessed using the Kaplan-Meier
method and compared using the log-rank test.
A P value of , .05 was considered signiﬁcant.
HR, hazard ratio.
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pathologic tumor response to chemotherapy, we hypothesize that
the survival beneﬁt demonstrated in the chemotherapy-plus-
surgery arm in the MAGIC trial may be due to tumor down-
staging (and more R0 resections) because lower T stages and
lower rates of lymph node involvement were seen in the che-
motherapy arm of the MAGIC trial; however, this could also be
a result of the effect of chemotherapy on micrometastatic disease,
which is not measured.
We also examined the effect of several molecular abnor-
malities on lymph node status and response to chemotherapy.
Interestingly, no signiﬁcant pathologic responses to chemotherapy
were detected in any patient with a KRAS, BRAF, or PIK3CA
mutation. The chemoresistant effect of RAS or PIK3CA pathway
activation has been described in non-small cell lung cancer and
colorectal preclinical models and clinically in patients with cervical
cancer; therefore, this may be a true effect. However, the current
analysis is limited by the small proportion of patients with mu-
tations.19-21 Patients who were HER2 positive also appeared less
likely to demonstrate a signiﬁcant pathologic response to ECF
chemotherapy. Preclinical data to support this result have recently
been described; however, HER2-positive patients with esoph-
agogastric cancer have not previously been demonstrated to have
inferior response rates to chemotherapy.22 In the Trastuzumab
for Gastric Cancer trial, the radiologic response rate to cisplatin-
ﬂuoropyrimidine therapy was 35%, which is consistent with other
similar data sets.23,24 We have also previously demonstrated that
HER2 status in MAGIC was not associated with differential sur-
vival outcomes, and we believe that this result requires further
veriﬁcation.13
As Lauren’s diffuse tumors may have a signiﬁcant stromal
element, it is challenging to perform pathologic response
assessment in this subtype of gastric cancer. In our study, neither
Lauren’s histologic subtype was statistically signiﬁcantly more
likely to demonstrate a good pathologic response to chemotherapy
overall. However, we did not evaluate the presence of signet ring
cells, which have in several series been associated with reduced
rates of response to chemotherapy.25 It is possible that this unique
group of patients may have different outcomes; however, because
only 18% of patients (n = 58) in our cohort had Lauren’s diffuse
cancer, the current analysis may be underpowered to evaluate this
subset.26
A potential limitation of our analysis is that we were unable to
include all patients from the MAGIC trial in this study because we
did not receive material from the entire patient cohort. However,
because survival after chemotherapy was not different for those
who did not have tissue available for analysis compared with the
patients analyzed, we do not believe that this introduced signiﬁcant
bias. The optimal system for assessment of pathologic tumor
regression is contentious.27,28 We chose the Mandard system, and
although we acknowledge that this classiﬁcation system was ini-
tially designed for patients with esophageal squamous cell cancer
undergoing chemoradiotherapy, it is the most widely used system
in esophagogastric cancer. Alternative systems include those
proposed by Becker et al,29 Dworak et al,30 and Ro¨del et al.31 The
Dworak et al30 and Ro¨del et al31 systems were designed for rectal
adenocarcinomas following chemoradiotherapy, and the Becker
et al29 system (which was designed speciﬁcally for assessment in
chemotherapy-treated patients with gastric cancer) requires review
of the entire tumor bed, which was not available for all MAGIC
specimens. Because only a representative block was chosen for this
assessment, it is therefore likely that the block with the most tumor
was chosen, and if the underlying cancer demonstrates hetero-
geneity of response to chemotherapy, then the assessment will be
biased toward nonresponders. Reassuringly, our ﬁndings are
similar to those from a large study published using the Becker
et al29 criteria, in which tumor stage (incorporating lymph node
status) but not tumor regression was an independent prognostic
factor after neoadjuvant therapy.16
In the MAGIC trial, fewer than half of patients completed all
protocol chemotherapy. Because postoperative morbidity after
esophagogastrectomy is considerable, there is often a sound clinical
rationale for this. For these patients, the absence of a signiﬁcant
pathologic response in the resection specimen may lead to re-
luctance to complete postoperative chemotherapy. These data are
not presented with the intention of inﬂuencing any change in
practice with respect to use of perioperative chemotherapy;
however, it is intuitively tempting to directly compare the median
survival of node-positive nonresponders in the chemotherapy arm
with node-positive surgery alone. Chemotherapy-treated patients
who are node positive after surgery and who have no signiﬁcant
pathologic response (TRG 3, 4, or 5) in the resected primary tumor
have a survival outcome inferior to those whowere not treated with
chemotherapy. However, it is possible that the survival of those
in the chemotherapy arm could have been even worse without
chemotherapy. Finally, for the avoidance of nihilism, it is also
important to note that even the patients with a poor pathologic
response have a chance of cure (28.9% 5-year survival in our
model). Thus, even a modest response to chemotherapy may play
an important role in survival outcomes, and TRG may not be
Ov
er
al
l S
ur
vi
va
l (
%
) 
Time From Surgery (years) 
20
40
60
80
100
0 1 2 3 4 5 6 7 8 9 10
TRG 1-2 and node negative
TRG 1-2 and node positive
TRG 3-4-5 and node negative
TRG 3-4-5 and node positive
Subjects Events HR (95% CI) P
15 6 1 (< .001)
12 6 2.06 (0.65 to 6.43)  .02
19 5 0.78 (0.23 to 2.56)    .676
64 50 3.44 (1.44 to 8.21)    .005
Fig 4. Overall survival by tumor regression grade (TRG) and lymph node status in
patients treated with chemotherapy plus surgery in the Medical Research Council
Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial. Patients were stratiﬁed
into four groups: ypN0 and TRG 1 or 2 (node-negative responders); ypN1+ TRG 1 or
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ferences in overall survival were assessed using the Kaplan-Meier method and
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HR, hazard ratio.
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sensitive to these changes. The only ﬁrm conclusion that can cur-
rently be made is that node-positive nonresponders are a relatively
poor prognosis group, and only a future randomized trial can ac-
curately determine whether changing or intensifying treatment of
nonresponders will result in improvements in OS for these patients.
In conclusion, our study demonstrates that in patients with
gastroesophageal cancer treated with perioperative ECF chemo-
therapy, the lymph node status in the resection specimen and not
the regression of the primary tumor is the primary arbiter
of survival. Although 18F-labeled ﬂuorodeoxyglucose-positron
emission tomography/computed tomography response in the
primary tumor has been validated as a predictive marker of OS
after a single cycle of chemotherapy in two studies, we do not know
how this relates to lymph nodes status nor whether switching to
a noncross-resistant chemotherapy regimenwill result in improved
survival32-34; this question may be answered by an ongoing
US clinical trial (NCT02485834), in which patients who are
18F-labeled ﬂuorodeoxyglucose-positron emission tomography
nonresponders are randomly assigned to surgery followed by
chemoradiation or to salvage perioperative chemotherapy. In the
interim, because the median survival for patients with resectable
Western gastroesophageal cancer undergoing potentially curative
surgery is fewer than 3 years, further work is required to identify
more effective therapies and improve outcomes.8
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS
OF INTEREST
Disclosures provided by the authors are available with this article at
www.jco.org.
AUTHOR CONTRIBUTIONS
Conception and design: Elizabeth C. Smyth, David Cunningham, Nicola
Valeri
Financial support: David Cunningham, Nicola Valeri
Administrative support: David Cunningham
Provision of study materials: David Cunningham, Massimo Rugge,
Nicola Valeri
Collection and assembly of data: Elizabeth C. Smyth,Matteo Fassan, David
Cunningham, WilliamH. Allum, Alicia F.C. Okines, Andrea Lampis, Jens C.
Hahne, Massimo Rugge, MatthewNankivell, Ruth Langley, Michele Ghidini,
Chiara Braconi, Andrew Wotherspoon, Heike I. Grabsch, Nicola Valeri
Data analysis and interpretation: Elizabeth C. Smyth, Matteo Fassan,
David Cunningham, William H. Allum, Alicia F.C. Okines, Andrea Lampis,
Jens C. Hahne, Massimo Rugge, Clare Peckitt, Matthew Nankivell, Ruth
Langley, Chiara Braconi, Andrew Wotherspoon, Heike I. Grabsch, Nicola
Valeri
Manuscript writing: All authors
Final approval of manuscript: All authors
REFERENCES
1. Medical Research Council Oesophageal Can-
cer Working Group: Surgical resection with or with-
out preoperative chemotherapy in oesophageal
cancer: A randomised controlled trial. Lancet 359:
1727-1733, 2002
2. Cunningham D, Allum WH, Stenning SP, et al:
Perioperative chemotherapy versus surgery alone for
resectable gastroesophageal cancer. N Engl J Med
355:11-20, 2006
3. van Hagen P, Hulshof MCCM, van Lanschot
JJB, et al: Preoperative chemoradiotherapy for
esophageal or junctional cancer. N Engl J Med 366:
2074-2084, 2012
4. Ychou M, Boige V, Pignon J-P, et al: Peri-
operative chemotherapy compared with surgery
alone for resectable gastroesophageal adenocarci-
noma: An FNCLCC and FFCD multicenter phase III
trial. J Clin Oncol 29:1715-1721, 2011
5. Kattan MW, Karpeh MS, Mazumdar M, et al:
Postoperative nomogram for disease-speciﬁc sur-
vival after an R0 resection for gastric carcinoma.
J Clin Oncol 21:3647-3650, 2003
6. Novotny AR, Schuhmacher C, Busch R, et al:
Predicting individual survival after gastric cancer re-
section: Validation of a U.S.-derived nomogram at
a single high-volume center in Europe. Ann Surg 243:
74-81, 2006
7. Peeters KC, Kattan MW, Hartgrink HH, et al:
Validation of a nomogram for predicting disease-
speciﬁc survival after an R0 resection for gastric
carcinoma. Cancer 103:702-707, 2005
8. Alderson D, Langley RE, Nankivell MG, et al:
Neoadjuvant chemotherapy for resectable oeso-
phageal and junctional adenocarcinoma: Results
from the UK Medical Research Council randomised
OEO5 trial (ISRCTN 01852072). ASCO Meeting Ab-
stracts 33:4002, 2015 (abstr)
9. National Comprehensive Cancer Network:
NCCN gastric cancer guidelines (ed version 3.0).
www.nccn.org/professionals/physician_gls/pdf/gastric.
pdf
10. Waddell T, Verheij M, Allum W, et al: Gastric
cancer: ESMO-ESSO-ESTRO Clinical Practice Guide-
lines for diagnosis, treatment and follow-up. Ann
Oncol 24:vi57-vi63, 2013 (suppl 6)
11. Mandard AM, Dalibard F, Mandard JC, et al:
Pathologic assessment of tumor regression after
preoperative chemoradiotherapy of esophageal car-
cinoma. Clinicopathologic correlations. Cancer 73:
2680-2686, 1994
12. Lauren P: The two histological main types of
gastric carcinoma: Diffuse and so-called intestinal-
type carcinoma. An attempt at a histo-clinical clas-
siﬁcation. Acta Pathol Microbiol Scand 64:31-49,
1965
13. Okines AF, Thompson LC, Cunningham D,
et al: Effect of HER2 on prognosis and beneﬁt from
peri-operative chemotherapy in early oesophago-
gastric adenocarcinoma in the MAGIC trial. Ann
Oncol 24:1253-1261, 2013
14. Okines AF, Gonzalez de Castro D, CunninghamD,
et al: Biomarker analysis in oesophagogastric cancer: Re-
sults from theREAL3andTransMAGIC trials. Eur JCancer
49:2116-2125, 2013
15. Smyth EC, Hulkki Wilson S, Nankivell MG,
et al: Effect of TP53 mutation status on survival in the
MAGIC trial. ASCO Meeting Abstracts 33:71, 2015
(abstr)
16. Schmidt T, Sicic L, Blank S, et al: Prognostic
value of histopathological regression in 850 neo-
adjuvantly treated oesophagogastric adenocarci-
nomas. Br J Cancer 110:1712-1720, 2014
17. Mansour JC, Tang L, Shah M, et al: Does
graded histologic response after neoadjuvant che-
motherapy predict survival for completely resected
gastric cancer? Ann Surg Oncol 14:3412-3418,
2007
18. Songun I, Putter H, Kranenbarg EM-K, et al:
Surgical treatment of gastric cancer: 15-year follow-
up results of the randomised nationwide Dutch D1D2
trial. Lancet Oncol 11:439-449, 2010
19. Tao S, Wang S, Moghaddam SJ, et al: On-
cogenic KRAS confers chemoresistance by upregu-
lating NRF2. Cancer Res 74:7430-7441, 2014
20. Fichtner I, Slisow W, Gill J, et al: Anticancer
drug response and expression of molecular markers
in early-passage xenotransplanted colon carcinomas.
Eur J Cancer 40:298-307, 2004
21. Wang J, Chai YL, Wang T, et al: Genetic al-
terations of PIK3CA and tumor response in patients
with locally advanced cervical squamous cell carci-
noma treated with cisplatin-based concurrent che-
moradiotherapy. Exp Mol Pathol 98:407-410, 2015
22. Huang D, Duan H, Huang H, et al: Cisplatin
resistance in gastric cancer cells is associated with
HER2 upregulation-induced epithelial-mesenchymal
transition. Sci Rep 6:20502, 2016
23. Ohtsu A, Shah MA, Van Cutsem E, et al:
Bevacizumab in combination with chemotherapy as
ﬁrst-line therapy in advanced gastric cancer: A ran-
domized, double-blind, placebo-controlled phase III
study. J Clin Oncol 29:3968-3976, 2011
24. Bang Y-J, Van Cutsem E, Feyereislova A, et al:
Trastuzumab in combination with chemotherapy
versus chemotherapy alone for treatment of HER2-
positive advanced gastric or gastro-oesophageal
junction cancer (ToGA): A phase 3, open-label,
randomised controlled trial. Lancet 376:687-697,
2010
25. Heger U, Blank S, Wiecha C, et al: Is pre-
operative chemotherapy followed by surgery the
appropriate treatment for signet ring cell containing
adenocarcinomas of the esophagogastric junction
and stomach? Ann Surg Oncol 21:1739-1748, 2014
26. Voron T, Messager M, Duhamel A, et al: Is
signet-ring cell carcinoma a speciﬁc entity
among gastric cancers? Gastric Cancer 10.1007/
2726 © 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Smyth et al
Downloaded from ascopubs.org by University of Leeds - Periodicals Department on December 19, 2016 from 129.011.023.117
Copyright © 2016 American Society of Clinical Oncology. All rights reserved.
s10120-015-0564-2 [epub ahead of print on
November 25, 2015]
27. Thies S, Langer R: Tumor regression grading
of gastrointestinal carcinomas after neoadjuvant
treatment. Front Oncol 3:262, 2013
28. Provenzano E, Bossuyt V, Viale G, et al: Stan-
dardization of pathologic evaluation and reporting of
postneoadjuvant specimens in clinical trials of breast
cancer: Recommendations from an international
working group. Mod Pathol 28:1185-1201, 2015
29. Becker K, Mueller JD, Schulmacher C, et al:
Histomorphology and grading of regression in gastric
carcinoma treated with neoadjuvant chemotherapy.
Cancer 98:1521-1530, 2003
30. Dworak O, Keilholz L, Hoffmann A: Patho-
logical features of rectal cancer after preoperative
radiochemotherapy. Int J Colorectal Dis 12:19-23,
1997
31. Ro¨del C, Martus P, Papadoupolos T, et al:
Prognostic signiﬁcance of tumor regression after
preoperative chemoradiotherapy for rectal cancer.
J Clin Oncol 23:8688-8696, 2005
32. zum Bu¨schenfelde CM, Herrmann K, Schuster
T, et al: (18)F-FDG PET-guided salvage neoadjuvant
radiochemotherapy of adenocarcinoma of the
esophagogastric junction: The MUNICON II trial.
J Nucl Med 52:1189-1196, 2011
33. Lordick F, Ott K, Krause B-J, et al: PET to
assess early metabolic response and to guide
treatment of adenocarcinoma of the oesophago-
gastric junction: The MUNICON phase II trial. Lancet
Oncol 8:797-805, 2007
34. Krause BJ, Herrmann K, Wieder H, et al:
18F-FDG PET and 18F-FDG PET/CT for assessing re-
sponse to therapy in esophageal cancer. J Nucl Med
50:89S-96S, 2009 (suppl 1)
n n n
www.jco.org © 2016 by American Society of Clinical Oncology 2727
Tumor Regression Grading and Survival in MRC MAGIC Trial
Downloaded from ascopubs.org by University of Leeds - Periodicals Department on December 19, 2016 from 129.011.023.117
Copyright © 2016 American Society of Clinical Oncology. All rights reserved.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Effect of Pathological Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy
Trial
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are
self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more
information about ASCO’s conﬂict of interest policy, please refer to www.asco.org/rwc or jco.ascopubs.org/site/ifc.
Elizabeth C. Smyth
Consulting or Advisory Role: Five Prime Therapeutics
Honoraria: Five Prime Therapeutics
Matteo Fassan
No relationship to disclose
David Cunningham
Research Funding: AstraZeneca (Inst), Amgen (Inst), Merck Serono
(Inst), Sanoﬁ (Inst), Merrimack (Inst), Celgene (Inst), MedImmune (Inst),
Bayer (Inst)
William H. Allum
Honoraria: Eli Lilly, Nestle, Taiho Pharmaceutical
Alicia F.C. Okines
No relationship to disclose
Andrea Lampis
No relationship to disclose
Jens C. Hahne
No relationship to disclose
Massimo Rugge
No relationship to disclose
Clare Peckitt
Honoraria: Sanoﬁ
Matthew Nankivell
No relationship to disclose
Ruth Langley
Honoraria: Bayer
Consulting or Advisory Role: Bayer (Inst)
Michele Ghidini
No relationship to disclose
Chiara Braconi
No relationship to disclose
Andrew Wotherspoon
Travel, Accommodations, Expenses: Ventana Medical Systems
Heike I. Grabsch
No relationship to disclose
Nicola Valeri
Patents, Royalties, Other Intellectual Property: Approved patents and
pending applications for microRNA-related technology
© 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Smyth et al
Downloaded from ascopubs.org by University of Leeds - Periodicals Department on December 19, 2016 from 129.011.023.117
Copyright © 2016 American Society of Clinical Oncology. All rights reserved.
Appendix
Table A1. Comparison of OS (calculated from time of surgery) in Patients in the
Chemotherapy-Plus-Surgery Arm With and Without Mandard TRG Score
Subjects Events Median OS 95% CI P
TRG available 150 90 23.4 16.8 to 42.4
TRG not available 65 39 21.6 9.6 to NR .645
Abbreviations: NR, not reached; OS, overall survival; TRG, tumor regression
grade.
Table A2. Association Between Clinicopathologic Variables and Response to
Chemotherapy
Variable Odds Ratio (95% CI) P
Age, years
Overall .744
, 60
60 to 70 1.37 (0.60 to 3.18) .455
$ 70 1.07 (0.40 to 2.82) .896
Site
Overall .14
Lower esophagus
Esophagogastric junction 6.00 (1.02 to 35.3) .047
Stomach 3.16 (0.69 to 14.3) .137
Sex
Female
Male 0.84 (0.34 to 2.08) .709
Histology
Diffuse
Others 0.51 (0.20 to 1.31) .163
www.jco.org © 2016 by American Society of Clinical Oncology
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Table A3. Univariate Analysis of Factors Affecting Overall Survival in Patients
Treated With Chemotherapy Plus Surgery (n = 150)
Variables HR (95% CI) P
Age, years
, 60 .122
60 to , 70 1.42 (0.88 to 2.30) .150
$ 70 1.70 (1.00 to 2.90) .051
Sex
Female
Male 1.60 (0.89 to 2.88) .117
WHO score
Normal activity
Restricted 1.10 (0.71 to 1.72) .669
Site
Lower esophagus .113
Esophagogastric junction 0.39 (0.15 to 1.01) .052
Stomach 0.63 (0.36 to 1.10) .106
Histology
Diffuse .754
Intestinal 1.11 (0.62 to 2.00) .702
MI + diff/other 1.10 (0.14 to 8.41) .928
Not assessed 3.12 (0.40 to 24.2) .276
TRG score
1-2
3-5 1.94 (1.11 to 3.39) .021
N stage
Node-negative
Node-positive 3.63 (1.88 to 7.00) , .001
Abbreviation: HR, hazard ratio; MI + diff/other, mixed intestinal and diffuse or
other; TRG, tumor regression grade.
Table A4. Multivariate Analysis of Factors Affecting Overall Survival in Patients
Treated With Chemotherapy Plus Surgery (n = 110)
Variable HR (95% CI) P
TRG
3-5 1.32 (0.69 to 2.52) .411
N stage
Node positive 3.36 (1.70 to 6.63) , .001
Abbreviations: HR, hazard ratio; TRG, tumor regression grade.
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